# US 2016/0354330 A1 · Treatment of levodopa-induced dyskinesias

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354330 A1
- Document ID: US20160354330A1
- Status: Published application
- Kind: A1
- Application number: 15/147,092
- Filed: 2016-05-05
- Published: 2016-12-08
- Earliest claimed: 2015-05-05
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Dalton James Surmeier; Weixing Shen; Zhong Xie
- Web page: https://patentgrep.com/patent/US20160354330A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are compositions and methods for the treatment and prevention of levodopa-induced dyskinesias (LID). In particular, M4 muscarinic receptor (M4R) positive allosteric modulators (PAMs) are administered to reduce dyskinetic behavior.

## Claims

### Claim 1

A method of treating a psychomotor disease comprising co-administering levodopa and a 4 muscarinic receptor (M4R) positive allosteric modulator (PAM) to a subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the psychomotor disease is Parkinson's disease (PD).

### Claim 3 (depends on 1)

The method of claim 1, wherein the levodopa and M4R-PAM are administered simultaneously.

### Claim 4 (depends on 3)

The method of claim 3, wherein the levodopa and M4R-PAM are co-formulated.

### Claim 5 (depends on 1)

The method of claim 1, wherein the levodopa and M4R-PAM are administered sequentially and in separate pharmaceutical formulations.

### Claim 6 (depends on 1)

The method of claim 1, wherein the M4R-PAM is a small molecule.

### Claim 7 (depends on 6)

The method of claim 6, wherein the M4R-PAM is selected from the group consisting of VU0467154, VU010010, and VU152100.

### Claim 8

A method of treating levodopa-induced dyskinesias (LID) in a subject being treated with levodopa comprising administering an M4R PAM.

### Claim 9 (depends on 8)

The method of claim 8, wherein the psychomotor disease is Parkinson's disease (PD).

### Claim 10 (depends on 8)

The method of claim 8, wherein the levodopa and M4R-PAM are administered simultaneously.

### Claim 11 (depends on 10)

The method of claim 10, wherein the levodopa and M4R-PAM are co-formulated.

### Claim 12 (depends on 8)

The method of claim 8, wherein the levodopa and M4R-PAM are administered sequentially and in separate pharmaceutical formulations.

### Claim 13 (depends on 8)

The method of claim 8, wherein the M4R-PAM is a small molecule.

### Claim 14 (depends on 13)

The method of claim 13, wherein the M4R-PAM is selected from the group consisting of VU0467154, VU010010, and VU152100.

### Claim 15

A pharmaceutical composition comprising levodopa and an M4R PAM.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the M4R-PAM is a small molecule.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the M4R-PAM is selected from the group consisting of VU0467154, VU010010, and VU152100.

### Claim at position 18

18-25. (canceled)
